Personalized Search
Displaying 41 - 60 of 1184
Hypomethylating agents–venetoclax as salvage therapy for relapse of AML and MDS after allogeneic HCT
Key PointsHMA-VEN is well tolerated in patients with AML/MDS who relapsed after alloHCT.HMA-VEN is effective for relapsed AML/MDS after alloHCT, even in patients who have failed prior VEN-based regimens.AbstractRelapse after allogeneic hematopoietic cell transplantation (alloHCT) remains a challenge for patients with
acute myeloid leukemia
acute myeloid…
Article last updated
.
Background: Philadelphia-negative myeloproliferative neoplasms (MPNs), including essential thrombocythaemia (ET), polycythaemia vera (PV), and myelofibrosis (MF), usually affect older adults, but a subset occurs in adolescents and young adults (AYA). Regional age-stratified data remain limited.
Methods: We retrospectively studied Philadelphia-negative MPN patients managed at the National Center…
Article last updated
.
Highlights -Considerable heterogeneity exists in germline testing implementation across hematopoietic stem cell transplantation centers in the United States.-Lack of standardized protocols affects the timing of testing and inconsistent sample collection workflows.-Barriers to consistent care include insurance challenges, logistical constraints, and…
Article last updated
.
Key PointsPRCA shows marked diagnostic heterogeneity, where molecular data can help identify challenging secondary forms, such as MDS-associated cases.Early initiation of CyA improves outcomes; mTORi are valuable second-line treatment. Infection related mortality remains non negligible.Abstract
Pure red cell aplasia (PRCA)
Pure red cell aplasia (PRCA):
A…
Article last updated
.
Shane Pope talks about living with PNH, or Paroxysmal Nocturnal Hemglobinuria, in this recorded conversation with Leigh Clark. Listen or read the transcript below.
Podcast Episode last updated
.
Shaquilla Gordon explains her journey with the
bone marrow failure
bone marrow failure:
A condition that occurs when the bone marrow stops making enough healthy blood cells. The most common of these rare diseases are aplastic anemia, myelodysplastic syndromes (MDS) and paroxysmal nocturnal hemoglobinuria (PNH). Bone marrow failure can be acquired (begin any time in life) or can be……
Podcast Episode last updated
.
Weill Cornell Medicine investigators have developed a new AI-based method to assess patients with a form of blood cancer called myelodysplastic neoplasms. The method, published June 30 in Leukemia, compares the physical locations and morphometric (size and shape) characteristics of every hematopoietic cell in the patient’s
bone marrow
bone marrow:
The soft, spongy tissue inside most…
Article last updated
.
AbstractIntroduction
Azacitidine
Azacitidine:
It works by reducing the amount of methylation in the body. Methylation is a process that acts like a switch to turn off or “silence” genes in certain cells. When these genes (called tumor suppressor genes) are turned off, MDS cells and cancer cells can grow freely. Azacitidine is approved by the U…
-venetoclax (AZA-VEN) has become a standard…
Article last updated
.
ABSTRACTThe RACE study (NCT02009747) compared horse
antithymocyte globulin
antithymocyte globulin:
ATG is an immunosuppressant, a drug that lowers the body's immune response. It is typically used with cyclosporine as the first-line immunosuppressive therapy (IS) to treat patients with acquired aplastic anemia. In some cases it is used as a treatment for patients with MDS and PNH.
(hATG…
Article last updated
.
SummaryReduced-intensity conditioning (RIC) is associated with a high relapse rate in high-risk acute myeloid leukaemia (AML) and
myelodysplastic syndromes
myelodysplastic syndromes:
(my-eh-lo-diss-PLASS-tik SIN-dromez) A group of disorders where the bone marrow does not work well, and the bone marrow cells fail to make enough healthy blood cells. Myelo refers to the bone marrow.…
Article last updated
.
For most of the last 50 years, the conversation with a patient with newly diagnosed
acute myeloid leukemia
acute myeloid leukemia:
(uh-KYOOT my-uh-LOYD loo-KEE-mee-uh) A cancer of the blood cells. It happens when very young white blood cells (blasts) in the bone marrow fail to mature. The blast cells stay in the bone marrow and become to numerous. This slows production of red blood…
Article last updated
.
AbstractPurpose: To evaluate the efficacy and safety of the cluster of differentiation 47-targeted antibody magrolimab plus
azacitidine
azacitidine:
It works by reducing the amount of methylation in the body. Methylation is a process that acts like a switch to turn off or “silence” genes in certain cells. When these genes (called tumor suppressor genes) are turned off,…
Article last updated
.
In a single-center phase I to II trial (SAVE) reported in the Journal of Clinical Oncology, Issa et al found that the all-oral combination of revumenib,
decitabine
decitabine:
It works by reducing the amount of methylation in the body. Methylation is a process that acts like a switch to turn off or “silence” genes in certain cells. When these genes (called tumor suppressor genes) are…
Article last updated
.
TO THE EDITOR:In older patients with
acute myeloid leukemia
acute myeloid leukemia:
(uh-KYOOT my-uh-LOYD loo-KEE-mee-uh) A cancer of the blood cells. It happens when very young white blood cells (blasts) in the bone marrow fail to mature. The blast cells stay in the bone marrow and become to numerous. This slows production of red blood cells and platelets. Some cases of MDS become…
(…
Article last updated
.
Highlights•There are no differences in NRM in patients receiving prior CAR T versus no CAR T.•There are no differences in GVHD in patients receiving prior CAR T versus no CAR T.•HCT within 3 months of CAR T had less grades III to IV acute GVHD.ABSTRACTIt remains unclear whether prior chimeric antigen receptor (CAR) T-cell therapy is associated with an increased risk of
graft-versus-host…
Article last updated
.
To the editorU2 small nuclear RNA auxiliary factor 1 (U2AF1) is one of the most frequently mutated genes in myelodysplastic neoplasms (MDS) [1, 2]. U2AF1 mutations predominantly occur at two hotspots (S34, Q157) within two zinc finger domains and disrupt pre-mRNA splicing by altering RNA binding specificity, with S34 and Q157 variants affecting nucleotide recognition at the −3 and +1 positions of…
Article last updated
.
Learn from Dr. Richard Childs, RADM, as he explains the FDA approval of Omnisirge for treating patients with Severe
Aplastic Anemia
Aplastic Anemia:
(ay-PLASS-tik uh-NEE_mee-uh) A rare and serious condition in which the bone marrow fails to make enough blood cells - red blood cells, white blood cells, and platelets. The term aplastic is a Greek word meaning not to form. Anemia is a…
Podcast Episode last updated
.
Patients with
aplastic anemia
aplastic anemia:
(ay-PLASS-tik uh-NEE_mee-uh) A rare and serious condition in which the bone marrow fails to make enough blood cells - red blood cells, white blood cells, and platelets. The term aplastic is a Greek word meaning not to form. Anemia is a condition that happens when red blood cell count is low. Most…
,
paroxysmal nocturnal hemoglobinuria…
Conference Event last updated
.
CONFERENCE LOCATION:Heldrich Hotel 10 Livingston AvenueNew Brunswick, NJ 08901Parking: Complimentary hotel valet parking CONFERENCE AGENDA
Aplastic Anemia
Aplastic Anemia:
(ay-PLASS-tik uh-NEE_mee-uh) A rare and serious condition in which the bone marrow fails to make enough blood cells - red blood cells, white blood cells, and platelets. The term aplastic is a Greek…
Conference Event last updated
.